Caligan Partners’s Tango Therapeutics TNGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$62.4M Buy
2,501,246
+1,143
+0% +$29.8K 3.82% 6
2026
Q2
$78.2M Buy
2,500,103
+91,305
+4% +$2.26M 3.68% 6
2026
Q1
$50.4M Sell
2,408,798
-1,321,097
-35% -$18.4M 3.35% 9
2025
Q4
$33M Buy
+3,729,895
New +$32.1M 2.72% 9

Other funds holding TNGX

Caligan Partners's TNGX Position: Q3 2026 in Review

Caligan Partners increased its Tango Therapeutics (TNGX) stake by 0.05% in Q3 2026, buying an estimated $29.8K and bringing the position to 2,501,246 shares worth $62.4M. The position accounts for 3.82% of the portfolio, ranked #6.

Caligan Partners first reported a position in TNGX in Q4 2025 and has held it in 4 quarters since. The position peaked at $78.2M in Q2 2026. 257 funds tracked by Wall St. Rank hold TNGX as of Q3 2026.

  • Caligan Partners held 2,501,246 shares of Tango Therapeutics worth $62.4M as of Q3 2026.
  • Caligan Partners bought 1,143 Tango Therapeutics shares in Q3 2026, an estimated $29.8K.
  • Tango Therapeutics made up 3.82% of Caligan Partners's portfolio in Q3 2026, its #6 holding.
  • Caligan Partners first reported a position in Tango Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Caligan Partners's Tango Therapeutics position peaked at $78.2M in Q2 2026.
  • 257 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2026.

Based on Caligan Partners's 13F filing for Q3 2026, filed 16 Nov 2026.